Angina (Angina Pectoris) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina - Pipeline Review, H2 2016, provides an overview of the Angina (Cardiovascular) pipeline landscape.

Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Angina - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Angina (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 2, 3 and 2 respectively for Angina.

Angina (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Angina (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Angina (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Angina (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Cardiovascular)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Angina (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Angina (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Angina (Angina Pectoris) Overview 7
Therapeutics Development 8
Pipeline Products for Angina (Angina Pectoris) - Overview 8
Angina (Angina Pectoris) - Therapeutics under Development by Companies 9
Angina (Angina Pectoris) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Angina (Angina Pectoris) - Products under Development by Companies 13
Angina (Angina Pectoris) - Companies Involved in Therapeutics Development 14
Amgen Inc. 14
Bayer AG 15
Juventas Therapeutics, Inc. 16
Kuhnil Pharmaceutical Co., Ltd. 17
Lee's Pharmaceutical Holdings Limited 18
LegoChem Biosciences, Inc 19
Milestone Pharmaceuticals, Inc. 20
Sanofi 21
Shire Plc 22
Taxus Cardium Pharmaceuticals Group Inc. 23
ViroMed Co., Ltd. 24
Angina (Angina Pectoris) - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
alferminogene tadenovec - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
BAY-606583 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
erenumab - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
etripamil - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
JVS-100 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
KI-1007 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
SAR-407899 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
VM-202 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ZK-001 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Angina (Angina Pectoris) - Dormant Projects 58
Angina (Angina Pectoris) - Discontinued Products 61
Angina (Angina Pectoris) - Product Development Milestones 62
Featured News & Press Releases 62
Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease 62
May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities 62
Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 64
Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted' 66
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 67
Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease 69
Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients 71
Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 71
Oct 23, 2007: Announcement of supplemental approval of indication of Sigmart Injection, a treatment drug for unstable angina pectoris 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

List of Tables

Number of Products under Development for Angina (Angina Pectoris), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Angina (Angina Pectoris) - Pipeline by Amgen Inc., H2 2016 14
Angina (Angina Pectoris) - Pipeline by Bayer AG, H2 2016 15
Angina (Angina Pectoris) - Pipeline by Juventas Therapeutics, Inc., H2 2016 16
Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2016 17
Angina (Angina Pectoris) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 18
Angina (Angina Pectoris) - Pipeline by LegoChem Biosciences, Inc, H2 2016 19
Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals, Inc., H2 2016 20
Angina (Angina Pectoris) - Pipeline by Sanofi, H2 2016 21
Angina (Angina Pectoris) - Pipeline by Shire Plc, H2 2016 22
Angina (Angina Pectoris) - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2016 23
Angina (Angina Pectoris) - Pipeline by ViroMed Co., Ltd., H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Angina (Angina Pectoris) - Dormant Projects, H2 2016 58
Angina (Angina Pectoris) - Dormant Projects (Contd..1), H2 2016 59
Angina (Angina Pectoris) - Dormant Projects (Contd..2), H2 2016 60
Angina (Angina Pectoris) - Discontinued Products, H2 2016 61